744 related articles for article (PubMed ID: 26858339)
1. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
4. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations.
Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE
J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D
Tumori; 2011; 97(4):532-9. PubMed ID: 21989445
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Andre F; Ismaila N; Allison KH; Barlow WE; Collyar DE; Damodaran S; Henry NL; Jhaveri K; Kalinsky K; Kuderer NM; Litvak A; Mayer EL; Pusztai L; Raab R; Wolff AC; Stearns V
J Clin Oncol; 2022 Jun; 40(16):1816-1837. PubMed ID: 35439025
[TBL] [Abstract][Full Text] [Related]
8. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
Pusina S
Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.
Yorozuya K; Takeuchi T; Yoshida M; Mouri Y; Kousaka J; Fujii K; Nakano S; Fukutomi T; Hara K; Ichihara S; Lin Y; Kikuchi S
J Cancer Res Clin Oncol; 2010 Jun; 136(6):939-44. PubMed ID: 19946706
[TBL] [Abstract][Full Text] [Related]
11. Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions.
Jayasekera J; Sparano JA; O'Neill S; Chandler Y; Isaacs C; Kurian AW; Kushi L; Schechter CB; Mandelblatt J
J Clin Oncol; 2021 Sep; 39(26):2893-2902. PubMed ID: 34251881
[TBL] [Abstract][Full Text] [Related]
12. Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer.
Lænkholm AV; Jensen MB; Eriksen JO; Roslind A; Buckingham W; Ferree S; Nielsen T; Ejlertsen B
Clin Breast Cancer; 2020 Aug; 20(4):e423-e432. PubMed ID: 32253134
[TBL] [Abstract][Full Text] [Related]
13. Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.
Dieci MV; Guarneri V; Zustovich F; Mion M; Morandi P; Bria E; Merlini L; Bullian P; Oliani C; Gori S; Giarratano T; Orvieto E; Griguolo G; Michieletto S; Saibene T; Del Bianco P; De Salvo GL; Conte P;
Oncologist; 2019 Nov; 24(11):1424-1431. PubMed ID: 31152079
[TBL] [Abstract][Full Text] [Related]
14. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
[TBL] [Abstract][Full Text] [Related]
15. Basal-like immunophenotype markers and prognosis in early breast cancer.
Cassol L; Silveira Graudenz M; Zelmanowicz A; Cancela A; Werutsky G; Rovere RK; Garicochea B
Tumori; 2010; 96(6):966-70. PubMed ID: 21388060
[TBL] [Abstract][Full Text] [Related]
16. Factors predictive of response to hormone therapy in breast cancer.
Rastelli F; Crispino S
Tumori; 2008; 94(3):370-83. PubMed ID: 18705406
[TBL] [Abstract][Full Text] [Related]
17. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Van Poznak C; Somerfield MR; Bast RC; Cristofanilli M; Goetz MP; Gonzalez-Angulo AM; Hicks DG; Hill EG; Liu MC; Lucas W; Mayer IA; Mennel RG; Symmans WF; Hayes DF; Harris LN
J Clin Oncol; 2015 Aug; 33(24):2695-704. PubMed ID: 26195705
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer assessment tools and optimizing adjuvant therapy.
Oakman C; Santarpia L; Di Leo A
Nat Rev Clin Oncol; 2010 Dec; 7(12):725-32. PubMed ID: 20975745
[TBL] [Abstract][Full Text] [Related]
19. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx.
Andre F; Ismaila N; Henry NL; Somerfield MR; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Van Poznak C; Wolff AC; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1956-1964. PubMed ID: 31150316
[TBL] [Abstract][Full Text] [Related]
20. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]